JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $248
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) but raises the price target from $160 to $248.
July 03, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Jessica Fye maintains a Neutral rating on Alnylam Pharmaceuticals but raises the price target from $160 to $248.
The raised price target from $160 to $248 by JP Morgan suggests a positive outlook for Alnylam Pharmaceuticals, which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100